Appreciation of the Quality of Life of Patients with Atopic Dermatitis. Clinical and Laboratory Study

Emanuela Duca^{1, 2}, Mariana Pascal^{1, 2}, Genel Sur^{2, 3}, Remus Gaga^1, and Lucia Sur^{1, 2}

¹University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj Napoca

²Clinical Emergency Hospital for Children, Cluj Napoca

³Pediatric Clinic II

Cite this paper:
Emanuela Duca, Mariana Pascal, Genel Sur, Remus Gaga and Lucia Sur. Appreciation of the Quality of Life of Patients with Atopic Dermatitis. Clinical and Laboratory Study. International Journal of Celiac Disease. 2021; 9(3):99-102. doi: 10.12691/ijcd-9-3-8

Abstract

Atopic dermatitis (AD) is an inflammatory disease of the skin that by evolution has autoimmune characters. The quality of life of patients with AD is an important objective in assessing the evolution and treatment of AD. Severity degrees were appreciated using diagnostic scores (SCORAD). Laboratory examinations come to complete the clinical diagnosis by determining total IgE, specific IgE, IL-31. These parameters allow us to appreciate the allergic component in AD.

Keywords:
atopic dermatitis quality of life allergic component

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Torres T, Ferreira EO, Gonçalo M, Mendes-Bastos P, Selores M, Filipe P.Update on Atopic Dermatitis.Acta Med Port. 2019 Sep 2; 32(9): 606-613.
[2]	Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, Vestergaard C, Seneschal J, Werfel T, Cork MJ, Kunz B, Fölster-Holst R, Trzeciak M, Darsow U, Szalai Z, Deleuran M, von Kobyletzki L, Barbarot S, Heratizadeh A, Gieler U, Hijnen DJ, Weidinger S, De Raeve L, Svensson Å, Simon D, Stalder JF, Ring J; European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.J Eur Acad Dermatol Venereol. 2020 Dec; 34(12): 2717-2744.
[3]	Patrick GJ, Archer NK, Miller LS.J Invest Dermatol. Which Way Do We Go? Complex Interactions in Atopic Dermatitis Pathogenesis. 2021 Feb; 141(2): 274-284.
[4]	Ha EK, Kim JH, Lee SW, Jee HM, Shin YH, Baek HS, Han MY.Atopic dermatitis: Correlation of severity with allergic sensitization and eosinophilia.Allergy Asthma Proc. 2020 Nov 1; 41(6): 428-435.
[5]	10.Atopic Dermatitis: Practice Essentials, Background, Pathophysiology [Internet]. Emedicine.medscape.com. 2021 (https://emedicine.medscape.com/article/1049085).
[6]	Wang V, Boguniewicz J, Boguniewicz M, Ong PY.The infectious complications of atopic dermatitis.Ann Allergy Asthma Immunol. 2021 Jan; 126(1): 3-12.
[7]	Matyas M, Hasmasanu MG, Zaharie G. Antioxidant Capacity of Preterm Neonates Assessed by Hydrogen Donor Value. Medicina (Kaunas). 2019 Oct 30;55(11): 720.
[8]	M.Matyas, D.Miclea, G.Zaharie. Case Report: Uncommon Association of ITGB4 and KRT10 Gene Mutation in a Case of Epidermolysis Bullosa With Pyloric Atresia and Aplasia Cutis Congenita.Frontiers in Genetics.June 2021 | Volume 12 | Article 641977.
[9]	Drislane C, Irvine A. The role of filaggrin in atopic dermatitis and allergic disease. Ann Allergy Asthma Immunol, 2020; 124: 36-43.
[10]	Özdoğru EE, Gönülal M.Dermatol Ther Atopic dermatitis, inhalant allergy and food allergy: A paediatric approach.Dermatol Ther. 2021 Jan; 34(1): e14542.
[11]	Kim J, Kim BE, Leung DYM Pathophysiology of atopic dermatitis: Clinical implications.
[12]	Allergy Asthma Proc. 2019 Mar 1; 40(2): 84-92.
[13]	Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis.
[14]	Ann Allergy Asthma Immunol. 2021 Jan; 126(1): 21-31.
[15]	Bawany F, Northcott CA, Beck LA, Peon WR. Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies. J Allergy Clin Immunol Pract. 2021 Apr; 9(4): 1488-1500.
[16]	Yang T, Kim B. Pruritus in allergy and immunology. J Allergy Clin Immunol, 2019; 144: 353-360.
[17]	Katoh N.J Dermatol. Emerging treatments for atopic dermatitis. 2021 Feb; 48(2): 152-157.